Establishment Labs Holdings Inc. (NASDAQ:ESTA) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET

Company Participants

Raj Denhoy - Chief Financial Officer
Juan Jose Chacon Quiros - Chief Executive Officer

Conference Call Participants

Allen Gong - JPMorgan
Anthony Petrone - Mizuho Group
Josh Jennings - TD Cowen
Joanne Wuensch - Citi
George Sellers - Stephens
Michael Toomey - Jefferies
Marie Thibault - BTIG

Operator

Good afternoon, and welcome to the Establishment Labs Reports Second Quarter 2024 Financial Results Call. At this time, all participants will be in a listen-only mode. At the end of this call, we will open the line for question-and-answer session and instructions will follow at that time. As a reminder this call is being recorded.

I would now like to turn the call over to Raj Denhoy, Chief Financial Officer. Please go ahead.

Raj Denhoy

Thank you, operator, and thank you everyone for joining us. With me today is Juan Jose Chacon Quiros, our Chief Executive Officer. Following our prepared remarks, we’ll take your questions.

Before we begin, I would like to remind you that comments made by management during this call will include forward-looking statements within the meaning of federal securities laws. These include statements on Establishment Labs’ financial outlook and the company’s plans and timing for product development and sales. These forward-looking statements are based on management’s current expectations and involve risks and uncertainties.

For a discussion of the principal risk factors and uncertainties that may affect our performance or cause actual results to differ materially from these statements, I encourage to review our most recent annual and quarterly reports on Form 10-K and Form 10-Q as well as other SEC filings, which are available on our website at establishmentlabs.com.

I’d also like to remind you that our comments may include certain non-GAAP financial measures with respect to our performance, including, but not limited to, sales results, which can be stated on a constant currency basis or profitability of the company’s business, which can be stated as EBITDA or adjusted EBITDA. Reconciliations to comparable GAAP financial measures for non-GAAP measures, if available, may be found in today’s press release, which is available on our website.

Please also note that Establishment Labs receive an investigational device exemption from the FDA for Motiva Implants and is undergoing a clinical trial to support regulatory approval in the United States. We continually seek to expand the geographies in which our products are regulatory approved. Please check with your local authority for product availability.